82_FR_43570 82 FR 43392 - Government-Owned Inventions; Availability for Licensing

82 FR 43392 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 178 (September 15, 2017)

Page Range43392-43393
FR Document2017-19590

Government owned intellectual property covering imaging agents with improved renal clearance available for licensing and commercialization.

Federal Register, Volume 82 Issue 178 (Friday, September 15, 2017) 
[Federal Register Volume 82, Number 178 (Friday, September 15, 2017)]
[Notices]
[Pages 43392-43393]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-19590]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Government owned intellectual property covering imaging agents 
with improved renal clearance available for licensing and 
commercialization.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479; 
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may 
be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The inventions listed below are owned by an 
agency of the U.S. Government and are available for licensing in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing. A description of the technology available for 
licensing follows.

Methods of Using Inhibitors To Enhance Therapeutic Uses of 
Endocannabinoids

    Description of Technology: The invention pertains to methods of 
using compounds that inhibit fatty acid amide hydrolase (FAAH) enzymes 
that are responsible for the degradation of oleamide and anandamide. 
Inhibition of degradation can be used as treatment modality for 
hypertension and for sleep disorders. The issued patent lists 
potentially useful compounds, one such useful compound in particular is
[GRAPHIC] [TIFF OMITTED] TN15SE.001


[[Page 43393]]


Potential Commercial Applications:
     Therapeutics for hypertension
     Therapeutics for anxiety disorders
     Therapeutics for sleep disorders
Development Stage:
     In vivo data available
Inventors: George Kunos and Alexandros Makriyannis (both of NIAAA)
Intellectual Property: HHS Reference No. E-211-2006/0-US-06.
     U.S. Patent 8,293,724 filed April 6, 2010, issued October 
23, 2012.

    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Environmental Health Sciences seeks statements of capability or 
interest from parties interested in collaborative research to further 
develop and evaluate, please contact Peg Koelble, Office of Technology 
Transfer, National Heart, Lung and Blood Institute, 
[email protected], 301-594-4095.

    Dated: September 7, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-19590 Filed 9-14-17; 8:45 am]
 BILLING CODE 4140-01-P

43392 Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices SUPPLEMENTARY INFORMATION: When awareness and use of the national toll- opioid crisis, and to definitively submitting comments or requesting free phone number. ascertain respondents’ knowledge of the information, please include the The Poison Help campaign aims to Poison Help Line and phone usage. information request collection title for reach a wide audience, as individuals of Likely Respondents: This study reference, in compliance with Section all ages are at risk for poisoning and includes two respondent groups, 3506(c)(2)(A) of the Paperwork may need to access PCC services. The individuals and households with an Reduction Act of 1995. ‘‘Poison Help General Population adult member 18 years and older. Information Collection Request Title: Survey’’ is a 10-minute telephone Burden Statement: Burden in this Poison Help General Population Survey survey designed to assess the context means the time expended by OMB Number 0915–0343, campaign’s impact among 2,000 persons to generate, maintain, retain, Reinstatement. households in the United States. The disclose, or provide the information Abstract: HRSA is requesting survey is conducted with an adult requested. This includes the time approval by OMB for reinstatement with household member and addresses topics needed to review instructions; to change of a previously approved related to the types of individuals or develop, acquire, install and utilize collection of information (OMB control organizations to contact for information, technology and systems for the purpose number 0915–0343). Annually, poison advice, and treatment related to a of collecting, validating and verifying control centers (PCCs) in the U.S. poisoning. information, processing and manage approximately 2.8 million calls, Need and Proposed Use of the maintaining information, and disclosing providing ready and direct access to Information: Survey results will be used and providing information; to train vital public health emergency to guide future communication, personnel and to be able to respond to information and response. In 2001, the education, and outreach efforts and will a collection of information; to search Poison Help line, a single, national toll- allow the tracking of longitudinal data data sources; to complete and review free phone number (800–222–1222) was from near-identical prior surveys the collection of information; and to established to ensure universal access to conducted in 2008 and 2011. The transmit or otherwise disclose the PCC services, 24 hours a day, 7 days a survey has been updated to include information. The total annual burden week. The Poison Help campaign is the questions regarding one of the Secretary hours estimated for this ICR are only national media effort to promote of HHS’ priority areas, addressing the summarized in the table below. TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS Number of Responses per Total Hours per Total burden Instrument respondents respondent responses response hours Survey Respondents ........................................................ 2000 1 2000 .166 332 Screened households ...................................................... 2600 1 2600 .016 41.6 Total .......................................................................... 4600 ............................ 4600 ........................ 374 Amy McNulty. FOR FURTHER INFORMATION CONTACT: applications are filed on selected Acting Director, Division of the Executive Licensing information and copies of the inventions to extend market coverage Secretariat. patent applications listed below may be for companies and may also be available [FR Doc. 2017–19608 Filed 9–14–17; 8:45 am] obtained by emailing the indicated for licensing. A description of the BILLING CODE 4165–15–P licensing contact at the National Heart, technology available for licensing Lung, and Blood, Office of Technology follows. Transfer and Development Office of DEPARTMENT OF HEALTH AND Technology Transfer, 31 Center Drive, Methods of Using Inhibitors To HUMAN SERVICES Room 4A29, MSC2479, Bethesda, MD Enhance Therapeutic Uses of 20892–2479; telephone: 301–402–5579. Endocannabinoids National Institutes of Health A signed Confidential Disclosure Description of Technology: The Government-Owned Inventions; Agreement may be required to receive invention pertains to methods of using Availability for Licensing copies of the patent applications. compounds that inhibit fatty acid amide AGENCY: National Institutes of Health, SUPPLEMENTARY INFORMATION: The hydrolase (FAAH) enzymes that are HHS. inventions listed below are owned by an responsible for the degradation of ACTION: Notice. agency of the U.S. Government and are oleamide and anandamide. Inhibition of available for licensing in the U.S. in degradation can be used as treatment SUMMARY: Government owned accordance with 35 U.S.C. 209 and 37 modality for hypertension and for sleep intellectual property covering imaging CFR part 404 to achieve expeditious disorders. The issued patent lists agents with improved renal clearance commercialization of results of potentially useful compounds, one such available for licensing and federally-funded research and useful compound in particular is commercialization. development. Foreign patent mstockstill on DSK30JT082PROD with NOTICES EN15SE.001</GPH> VerDate Sep<11>2014 17:07 Sep 14, 2017 Jkt 241001 PO 00000 Frm 00068 Fmt 4703 Sfmt 4725 E:\FR\FM\15SEN1.SGM 15SEN1

Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices 43393 Potential Commercial Applications: MD 20892, tel: 301–496–2644, fax: 240– No. PCT/US2017/021573 filed on 03/09/ • Therapeutics for hypertension 627–3117. A signed Confidential 2017. • Therapeutics for anxiety disorders Disclosure Agreement will be required Licensing Contact: Chris Kornak, 240– • Therapeutics for sleep disorders to receive copies of unpublished patent 627–3705, chris.kornak@nih.gov. Development Stage: applications. Collaborative Research Opportunity: • In vivo data available SUPPLEMENTARY INFORMATION: The Technology Transfer and Inventors: George Kunos and Technology description follows. Intellectual Property Office (TTIPO) is Alexandros Makriyannis (both of seeking parties interested in NIAAA) Recombinant HIV-1 Envelope Proteins collaborative research to further develop Intellectual Property: HHS Reference and Their Use the technology. In particular, NIAID is No. E–211–2006/0–US–06. Description of Technology: Millions of interested in partnerships utilizing • U.S. Patent 8,293,724 filed April 6, people are infected with HIV-1 vector vaccine platforms for expressing 2010, issued October 23, 2012. worldwide. In the U.S., there are about these immunogens. Licensing Contact: Michael 30,000 new cases of HIV infection However, NIAID is willing to discuss Shmilovich, Esq, CLP; 301–435–5019; reported annually. Currently, there are other applications of this technology. shmilovm@nih.gov. effective, anti-retroviral therapeutics For collaboration opportunities, please Collaborative Research Opportunity: available to treat or prevent HIV contact Chris Kornak, 240–627–3705, The National Institute of Environmental infection. However, available anti- chris.kornak@nih.gov. Health Sciences seeks statements of retroviral therapeutics require life-long Dated: September 7, 2017. capability or interest from parties administration. Suzanne Frisbie, interested in collaborative research to During infection, proteases of the host Deputy Director, Technology Transfer and further develop and evaluate, please cell cleave gp160 into gp120 and gp41. Intellectual Property Office, National Institute contact Peg Koelble, Office of Gp41 is an integral membrane protein, of Allergy and Infectious Diseases. Technology Transfer, National Heart, while gp120 protrudes from the mature [FR Doc. 2017–19591 Filed 9–14–17; 8:45 am] Lung and Blood Institute, koelblep@ virus. Together gp120 and gp41 BILLING CODE 4140–01–P nhlbi.nih.gov, 301–594–4095. aggregate as trimers that make up the Dated: September 7, 2017. HIV-1 envelope (‘‘Env’’) spike, which is Michael Shmilovich, a target for neutralizing antibodies. DEPARTMENT OF HEALTH AND NIAID researchers have constructed a HUMAN SERVICES Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, recombinant HIV-1 trimer immunogen. Office of Technology Transfer and In particular, the recombinant gp120 National Institutes of Health Development. protein in the trimer is stabilized in a [FR Doc. 2017–19590 Filed 9–14–17; 8:45 am] closed conformation, preventing it from National Institute on Deafness and binding to CD4. The advantage of the Other Communication Disorders; BILLING CODE 4140–01–P closed conformation is that it can Notice of Closed Meetings stabilize the epitopes that bind to Pursuant to section 10(d) of the DEPARTMENT OF HEALTH AND broadly neutralizing antibodies, Federal Advisory Committee Act, as HUMAN SERVICES minimize the binding of gp120 with amended, notice is hereby given of the weakly or non-neutralizing antibodies, following meetings. National Institutes of Health and prevent conformational changes The meetings will be closed to the induced by CD4 as well as immunogen public in accordance with the Government-Owned Inventions; sequestration by CD4 in vivo. Research provisions set forth in sections Availability for Licensing has also indicated that recombinant Env 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., AGENCY: National Institutes of Health, ectodomain trimers can induce higher as amended. The grant applications and HHS. neutralizing antibody titers than wild the discussions could disclose type Env trimers in animal models. confidential trade secrets or commercial ACTION: Notice. This technology is available for property such as patentable material, SUMMARY: The inventions listed below licensing for commercial development and personal information concerning are owned by an agency of the U.S. in accordance with 35 U.S.C. 209 and 37 individuals associated with the grant Government and are available for CFR part 404, as well as for further applications, the disclosure of which licensing to achieve expeditious development and evaluation under a would constitute a clearly unwarranted commercialization of results of research collaboration. invasion of personal privacy. federally-funded research and Potential Commercial Applications: Name of Committee: National Institute on development. Foreign patent • HIV-1 immunogen Deafness and Other Communication applications are filed on selected • New methods for isolating broadly Disorders Special Emphasis Panel; Chemical inventions to extend market coverage neutralizing antibodies Senses Fellowship Review. Competitive Advantages: Date: October 11, 2017. for companies and may also be available • A new strategy in inducing immune Time: 12:30 p.m. to 3:00 p.m. for licensing. response against HIV-1 Agenda: To review and evaluate grant FOR FURTHER INFORMATION CONTACT: Development Stage: applications. Chris Kornak, 240–627–3705, chris. • Pre-Clinical; Proof-of-concept Place: National Institutes of Health. kornak@nih.gov. Licensing information studies in nonhuman primate Neuroscience Center, 6001 Executive mstockstill on DSK30JT082PROD with NOTICES and copies of the U.S. patent models Boulevard, Rockville, MD 20852 (Telephone applications listed below may be Inventors: Conference Call). obtained by communicating with the Contact Person: Sheo Singh, Ph.D., Paolo Lusso, NIAID, NIH Scientific Review Officer, Scientific Review indicated licensing contact at the Peng Zhang, NIAID, NIH Branch, Division of Extramural Activities, Technology Transfer and Intellectual Publications: Pending. 6001 Executive Blvd., Room 8351, Bethesda, Property Office (TTIPO), 5601 Fishers Intellectual Property: HHS Reference MD 20892, 301–496–8683, singhs@ Lane, Suite 6D, MSC 9804, Rockville, No. E–102–2016/0—PCT Application nidcd.nih.gov. VerDate Sep<11>2014 17:07 Sep 14, 2017 Jkt 241001 PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 E:\FR\FM\15SEN1.SGM 15SEN1


Document Created: 2017-09-15 00:18:50
Document Modified: 2017-09-15 00:18:50
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
FR Citation82 FR 43392 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR